The product license was withdrawn due to the suspension of the operation of the Jansen Hyangnam plant in Korea, but the new product re-licensed due to technology transfer will be listed as starting in August. This includes child Tylenol suspension, and attention is being paid to whether supply and demand will be normalized with new benefits, given that the product has recently been struggling to supply. According to the industry, Ultracet ER, Ultracet Semi, Ultracet Semi ER, and Children's Tylenol suspension will be newly reimbursed as of August 1. The upper limit is the same as before. Following the withdrawal of the Hyangnam plant, the permission for these products was withdrawn in the first half of last year, and t